| 摘要 |
PCT No. PCT/EP94/03364 Sec. 371 Date Jun. 25, 1996 Sec. 102(e) Date Jun. 25, 1996 PCT Filed Oct. 12, 1994 PCT Pub. No. WO95/10521 PCT Pub. Date Apr. 20, 1995Compounds of formula (I) which includes pharmaceutically acceptable salts thereof and stereoisomers thereof: <IMAGE> (I) wherein: R1 represents H or one of the following groups (optionally substituted with one or more of halo, cyano, hydroxy or amino): C1-6 alkyl, C1-6 alkoxy or C1-6 alkanoyl; R2 and R3 independently represent H or one of the following groups (optionally substituted with one or more of halo, cyano, hydroxy or amino): C1-6 alkyl, C1-6 alkoxy or C1-6 alkanoyl, C1-6 alkylthio, C1-6 alkylsulphinyl or C1-6 alkylsulphonyl; R4 and R5 combined together with the carbon atom to which they are attached represent C3-6 cycloalkylidene (each alkyl or cycloalkylidene being optionally substituted with one or more of halo, cyano, hydroxy, amino or C1-6 alkyl); and R6, R7 and R8 independently represent H, halo, hydroxy, mercapto, cyano or one of the following groups (optionally substituted with one or more of halo, cyano, hydroxy or amino; and any nitrogen atom being optionally substituted with one or more C1-6 alkyl): C1-6 alkyl, C1-6 alkoxy or C1-6 alkanoyl, C1-6 alkylthio, C1-6 alkylsulphinyl, etc; have utility in the treatment and/or prophylaxis or seizures, neurological disorders such as epilepsy and/or conditions in which there is neurological damage such as stroke, brain trauma, head injuries and haemorrhage. |
